Articles tagged "Outcome"

2020 American Transplant Congress
A Data-Driven Approach to Defining the Volume-Outcome Relationship in Liver Transplantation
M. D. Bailey, E. L. Godfrey, W. C. Frankel, A. Rana
Baylor College of Medicine, Houston, TX
*Purpose: Patients with end-stage liver disease (ESLD) who undergo liver transplantation experience significant survival benefit, with a 1-year survival rate after liver transplantation of 91%.…
2020 American Transplant Congress
Total Penis, Scrotum, and Lower Abdominal Wall Transplant: 18-Month Update
D. S. Cooney¹, C. M. Cooney¹, V. Javia¹, J. T. Shores¹, A. L. Burnett², T. J. Bivalacqua², G. Brandacher¹, R. J. Redett¹
¹Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ²Urology, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: In 2018 we performed a total penis, scrotum, and lower abdominal wall transplant on a man who had sustained a loss of his bilateral…
2020 American Transplant Congress
Transition from Youth to Adult Care of Kidney Transplant Recipients: Single Center Experience
L. Ganesan, A. McGrath, K. Dahl, K. Dinello, A. Fong, L. Maestretti, M. Patton, P. Grimm, A. Chaudhuri
Pediatric Nephrology, Lucile Packard Children's Hospital, Stanford, CA
*Purpose: Transition of transplant recipients from youth to adult care has been a challenge for many. Starting in March 2017, Lucile Packard Children’s Hospital (LPCH)…
2020 American Transplant Congress
Effectiveness of Preemptive Therapy in the Prevention of Cytomegalovirus (CMV) Disease in High-Risk (Donor Seropositive/Recipient Seronegative) Liver Transplant Recipients
J. A. Morillas, K. Brizendine
Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Guidelines recommend preemptive therapy (PET) as one strategy for prevention of CMV disease in high risk liver transplant recipients (LTR). However, questions have been…
2020 American Transplant Congress
Metformin Improves Biomarkers of Calcineurin Inhibitor Related Nephrotoxicity
M. R. Fernando, K. Taylor, S. Herath, A. Au, J. Erlich, Z. Endre
Department of Nephrology, Prince of Wales Hospital, Randwick, Australia
*Purpose: Calcineurin Inhibitors (CNIs) prevent transplant rejection but cause significant nephrotoxicity. Biomarkers of CNI nephrotoxicity could help drug dosing and improve long-term graft outcomes. As…
2020 American Transplant Congress
Hepatocellular Carcinoma Locoregional Therapy: A Comparison of Radiologic Treatment Response and Post-Transplant Pathology
A. J. Hargrove¹, T. Donovan², K. Fisher³, M. Goodenberger⁴, A. Langnas¹, S. Merani¹
¹Department of Surgery, Division of Transplant Surgery, University of Nebraska Medical Center, Omaha, NE, ²Department of Radiology, Division of Interventional Radiology, University of Nebraska Medical Center, Omaha, NE, ³Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Radiology, Division of Body Imaging, University of Nebraska Medical Center, Omaha, NE
*Purpose: Transplantation or resection is the only potentially curative treatment for Hepatocellular Carcinoma (HCC). Locoregional therapy (LRT) is used exclusively in non-transplant candidates or as…
2020 American Transplant Congress
Post Heart Transplant Outcomes for Patients with Cardiac Sarcoidosis
G. S. Liu¹, E. C. DePasquale¹, A. M. Wolfson², R. R. Chand³, P. Banankhah¹, J. Nattiv¹, A. D. Salimbangon⁴, P. A. Genyk¹, P. A. Kingsford¹, J. P. Li¹, D. Vucicevic⁵, K. Pandya¹, J. Rahman¹, M. Fong¹, A. S. Vaidya¹
¹Keck Medicine of USC, Los Angeles, CA, ²University of Arizona Sarver Heart Center, Tucson, AZ, ³Harbor-UCLA Medical Center, Los Angeles, CA, ⁴UCLA Medical Center, Los Angeles, CA, ⁵Newark Beth Israel Medical Center, Newark, NJ
*Purpose: Cardiac sarcoidosis (CS) is a known etiology of end-stage dilated, hypertrophic, or arrhythmogenic cardiomyopathies requiring heart transplantation (HT). We sought to evaluate the long-term…
2020 American Transplant Congress
Donor-Specific Antibody Test as a Screening Tool for Stable Long-Term Kidney Transplant Recipients
M. Mohamed¹, L. Hidalgo², S. Parajuli¹, N. Garg¹, F. Aziz¹, K. Swanson¹, E. Jochaim¹, D. Mandelbrot¹, A. Djamali¹, B. Astor¹
¹Department of Nephrology, Madison, WI, ²Department of Surgery, Madison, WI
*Purpose: Donor-specific antibody (DSA) is an established biomarker predicting antibody mediated rejection (AMR), but at substantial cost. The utility of DSA test as a screening…
2020 American Transplant Congress
No Correlation Between Program-Specific Report Performance of Different Organs at the Same Center
A. Massie¹, N. Salkowski², D. Zaun², J. Snyder², D. Segev¹
¹Johns Hopkins, Baltimore, MD, ²SRTR, Minneapolis, MN
*Purpose: Transplant programs which have too many early graft failures, as determined by the SRTR Program-Specific Reports (PSRs) risk decreased patient volume, regulatory sanction, and…
2020 American Transplant Congress
Assessing Providers’ Accuracy in Predicting Early Readmission after Kidney and Liver Transplantation
K. Maroney, Z. Wang, R. Lynch, A. Adams, R. Patzer, J. Hogan
Emory University, Atlanta, GA
*Purpose: Predictive models capable of identifying patients at risk for readmission are in development. However, it is unknown how accurate clinicians are at predicting early…